** Sera Prognostics Inc's SERA.O down 7.6% in extended trading to $4.11 as it looks to raise equity
** Salt Lake City-based women's health co commences offering comprising stock and pre-funded warrants without disclosing deal size
** Co says plans to use net offering proceeds to expand commercial infrastructure in the U.S., accelerate preparations for expansion in the European Union, fund additional studies to increase adoption of its blood test to predict preterm birth risks, PreTRM, including a potential submission to U.S. FDA for broad approval
** Jefferies, TD Cowen and William Blair jt bookrunners for offering, joined by RBC
** Co has ~33.77 mln shares outstanding giving it a current market cap of ~$150 mln, per LSEG
** SERA shares on Mon closed down 2% at $4.45, extending YTD decline to 45%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.